Login to Your Account



Having the Nerf2 try: Bid in FA proves Reata moxie, pivotal tweaks aim for win

By Randy Osborne
Staff Writer

Friday, June 23, 2017

SAN DIEGO – After reporting upbeat data from the first part of an experiment with omaveloxolone for Friedreich's ataxia, Reata Pharmaceuticals Inc. has adjusted the second part for better chances of continued victory.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription